IRB vs Ethics Committee: Key Differences in Clinical Research

The site is contracted, and the budget is signed. Then the activation checklist stalls on one line: IRB approval pending.

For a U.S. site, that may mean waiting for an Institutional Review Board to review the protocol and other study documents. In a global study, the same step may involve a Research Ethics Committee (REC) or Independent Ethics Committee (IEC), depending on the country and regulatory framework.

The IRB vs. Ethics Committee sounds like a vocabulary question until it starts affecting your first-patient-in date. This guide explains how the terminology differs and what to expect from each review process.

What Is the Difference Between IRB and Ethics Committee?

The difference between IRB and Ethics Committee is jurisdiction and the regulatory framework governing the research. “IRB” is a defined term in US federal regulation. “Ethics committee” is the broader label used in ICH GCP guidance.

Individual countries then apply their own names, such as Research Ethics Committee (REC) in the UK, Research Ethics Board (REB) in Canada, and Human Research Ethics Committee (HREC) in Australia. The country where a trial runs decides which name appears on the approval letter.

The organizational structure can also vary. In the Institutional Review Board vs Ethics Committee comparison, US IRBs are often set up by university hospitals, research institutions, or independent commercial organizations. UK RECs operate as independent ethics review bodies.

IRB vs. Ethics Committee at a Glance

Sponsors usually handle these terms within wider regulatory affairs planning. The table below sets out the IRB vs. Ethics Committee comparison side by side.

The practical challenge is often regulatory alignment. A submission prepared for one country’s ethics review system may not meet another country’s requirements.

Differences in application forms, supporting documents, consent materials, fees, language requirements, and review procedures can delay site activation if they are not addressed early.

Does Every Clinical Trial Need IRB Approval?

Clinical research subject to FDA regulations generally requires IRB review before participants are enrolled, unless a specific regulatory exception applies. 21 CFR Part 56 establishes FDA requirements for IRB review and describes limited exceptions, including certain emergency uses of an investigational test article.

Some research may qualify for exemption from IRB review under applicable rules. For federally supported research subject to the Common Rule, 45 CFR Part 46 identifies eight specific categories of exempt research. Many interventional drug trials do not fall within these exempt categories.

Outside the US, national law requires its own ethics approval. In practice, the IRB vs. Ethics Committee question rarely changes whether review is needed. It only changes who performs it.

Once granted, the ethics approval becomes part of the trial’s essential documentation alongside other types of regulatory submissions and approvals required for the study.

What Is the Role of IRB in Clinical Trials?

An IRB provides an independent review of a study’s design and informed consent process. It can approve a study, require changes before approval, or disapprove it. It can also suspend or terminate approval when necessary to protect participants. That authority forms part of the broader work of regulatory affairs in clinical trials.

The role of an IRB in clinical trials is to determine whether risks are reasonable in relation to the anticipated benefit and whether the consent process provides participants with the information they need to make an informed decision.

FDA regulations also establish membership requirements to support diverse and independent review. An IRB generally must have at least five members, including:

• One member whose primary concerns are scientific.
• One member whose primary concerns are nonscientific.
• One member who is not otherwise affiliated with the institution.

What Are IRB Responsibilities?

Under FDA regulations, IRBs evaluate several aspects of participant protection, including:

• Risks are minimized and justified by the anticipated benefit.
• Participant selection is equitable.
• Informed consent is obtained and documented.
• Privacy and confidentiality are protected.
• Extra safeguards exist for vulnerable groups, such as children or prisoners.

Boards may also review protocol amendments, changes to informed consent materials, and other information that could affect participant protection. Depending on the study and applicable requirements, continuing review may also be required. Clinical trial monitoring can complement this oversight at the site level.

What Is the Role of Ethics Committee in Clinical Trials?

The role of an Ethics Committee in clinical trials overlaps with that of an IRB, although the applicable regulatory framework varies by region. ICH GCP requires committees to safeguard the rights, safety, and well-being of participants, with special attention to vulnerable groups. The ICH E6 guideline provides the international GCP framework for clinical trials.

National requirements then shape how each committee operates. Differences in timelines, forms, and committee structure can create regulatory challenges in clinical trials.

What Are Ethics Committee Responsibilities?

Ethics Committee responsibilities under ICH GCP reach beyond reviewing the protocol and consent form. A committee reviews:

• The investigator’s brochure and available safety information.
• The investigator’s qualifications, including a current CV.
• Recruitment methods and written information for participants.
• Payment and compensation arrangements for participants.

ICH E6 asks for continuing review at intervals suited to the degree of risk. It also sets a minimum of five members. At least one must be non-scientific, and one must be independent of the trial site.

How Do the IRB and Ethics Committee Review Processes Work?

Both processes follow a similar arc of submission, assessment, decision, and follow-up. The differences lie in what requirements apply and how the process is managed.

What Is the IRB Review Process?

The IRB review process usually follows these steps:

1. The sponsor or investigator submits the protocol, consent form, and recruitment materials.
2. The IRB staff checks the package for completeness.
3. The submission is assigned to the appropriate review pathway, such as exempt, expedited, or full board review.
4. Members review the submission and issue approval, required changes, or disapproval.
5. The study returns for amendment review and, when required, continuing review.

Since 2020, the revised Common Rule generally requires one IRB to review U.S.-based cooperative research. A CTMS that logs approval dates and document versions keeps this sequence traceable. This is one way CTMS supports regulatory submissions and document management throughout the study.

What Is the Ethics Committee Review Process?

The Ethics Committee review process follows a similar path but depends on the country. UK applicants file through the Integrated Research Application System, where a REC gives its opinion.

In the EU, the Clinical Trials Regulation has been applied since 31 January 2022. Sponsors submit through the Clinical Trials Information System. Member states coordinate the assessment, and national ethics requirements continue to apply.

Sponsors running studies across regions often rely on regulatory affairs services for clinical research to align submission packages before the first submission.

The Takeaway

An approval is more than a box to check before site activation. The IRB vs. Ethics Committee distinction can shape how long it takes to reach the first patient. Get the local requirements right from the start, and ethics review becomes part of the study timeline.

Minerva Research Solutions supports sponsors with regulatory and ethics submission requirements across regions, helping teams keep critical approvals moving toward study milestones.